Atlas Trials

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

Clinical trial NCT01670032 · COMPLETED

Trial details

NCT number
NCT01670032
Sponsor
NovaBay Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Impetigo
Start date
2012-08-01
Primary completion
2013-08-01
Enrollment
328

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.